PPD

NOVEMBER 11, 2024

It is hard to ignore some of the most pressing, long-term trends driving the push to accelerate innovation and progress in drug development. As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients.

Drug Development 52

Drug Development Clinical Trials Drugs Small Molecule 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

Drug Target Review

JULY 6, 2023

1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. How does TPD work?

Targeted Protein Degradation 98

Targeted Protein Degradation Small Molecule Clinical Trials Science 98

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. Chief Executive Officer of Biohaven, said: “We are excited to enter into this agreement with Sosei Heptares, a world leader in GPCR drug discovery. TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Here, researchers are looking at allosteric modulation—hitting different parts of the molecule to increase selectivity.

Small Molecule 67

Small Molecule RNA DNA Pharmaceutical Companies 67

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. UCSD, with its world-renowned Center for Microbiome Innovation , provides expertise in microbial genomics and drug discovery platforms.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

AUGUST 7, 2021

Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein is a leading global research and development-based pharmaceutical company headquartered in Japan.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. Cavlan notes that underpinning this use of AI in early discovery is the need to better understand biology.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Practical Cheminformatics

JANUARY 8, 2024

Picking up where we left off in Part I , this post covers several other ML in drug discovery topics that interested me in 2023. Most of the LLM activity in the drug discovery space in 2023 was reported as preprints from academic groups. Most of the drug discovery examples were underwhelming. Here’s the structure of Part II.

Drugs 141

Drugs Small Molecule Bioinformatics Packaging 141

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

KIF1A

JULY 1, 2023

Read the Pre-print Rare Roundup A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases We’ve spoken often about the goal of repurposing existing drugs to better treat KAND – this is a reality for many families who utilize off-label prescriptions.

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

The Pharma Data

APRIL 28, 2021

OSAKA, Japan, April 28, 2021 – Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. About Takeda Pharmaceutical Company Limited.

Packaging 52

Packaging Small Molecule Pharmaceutical Companies Engineering 52

The Pharma Data

SEPTEMBER 22, 2020

We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications,” said Matt Cooper, chief executive officer of Inflazome. Roche has plans to further develop Inflazome’s products across a wide range of indications with high unmet medical need. Source link.

Pharma Companies 52

Pharma Companies Small Molecule Pharmaceutical Companies Disease 52

The Pharma Data

APRIL 7, 2023

CycPeptMPDB, a novel database – created by Tokyo Tech researchers – focused on the membrane permeability of cyclic peptides, could accelerate the development of drugs based on these promising compounds. In principle, these compounds can achieve the fine balance required of modern drugs.

Small Molecule 40

Small Molecule Drugs Pharmaceutical Companies Research 40

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

Drug Target Review

MAY 23, 2023

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.

Drugs 75

Drugs Small Molecule Production Disease 75

Elrig

APRIL 29, 2024

Webinar | Ai At The Frontier: Empowering Early Career Professionals In Drug Discovery WEBINAR – ARE YOU CURIOUS ABOUT THE CUTTING-EDGE INTERSECTION OF ARTIFICIAL INTELLIGENCE AND DRUG DISCOVERY? Are you curious about the cutting-edge intersection of Artificial Intelligence and Drug Discovery?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. Developing new drugs is a critical technology of the 21 st century. The pandemic has shown Germany’s potential in innovating and manufacturing life-saving medications.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 X H NMR (500 MHz, DMSO-i¾) δ ppm 1.40 (d, J=6.8 49 (2): 121–132.

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

AUGUST 18, 2020

In this role, we are helping bring together Europe’s best and brightest scientific minds from 37 renowned academic institutions, research organizations and pharmaceutical companies, together with partners from the United States and China. Small molecule discovery. Virus-neutralizing antibody discovery. Source link.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In Berkien will join Ultimovacs from his current position at Amgen as Director Global Business Development.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Drug Target Review

JULY 7, 2023

Targeted therapies are designed to interfere with, or target, molecules such as proteins within the body. In some cases, the drug will attach to the molecule it targets, preventing it from doing its job. Other times, the drug will physically block the molecule from the place it normally goes.

Disease 98

Disease Immune Response Therapies Treatment 98

The Pharma Data

DECEMBER 13, 2020

Since its establishment, Viva Biotech has been providing comprehensive new drug R&D services to nearly 500 world’s top pharmaceutical and biotech companies based on Viva’s excellence in structure-based drug discovery.

Small Molecule 40

Small Molecule Computational Chemistry Pharmaceuticals Production 40

Drug Target Review

APRIL 19, 2024

Identifying new drugs is an extremely complex project. The scientific founders have developed a pioneering method for drug discovery that applies to the research and design of new drugs effective against diseases that are incurable to date. We are now in the preclinical stage of developing a proprietary drug pipeline.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

LifeSciVC

APRIL 27, 2023

The premise at the time was that putting computational chemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. Because the other thing that happened was the creation of an incredible discovery engine that entirely changed the small molecule drug discovery paradigm.

Small Molecule 52

Small Molecule Computational Chemistry Engineering Clinical Development 52

The Pharma Data

JULY 15, 2021

Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc. Vincent’s Institute of Medical Research (SVI)’s multi-year research collaboration with Janssen Pharmaceuticals, Inc.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

DECEMBER 15, 2020

CHIPCREEN BIOSCIENCES remains as the owner and manufacturer of the drug. Dr. Lu Xianping, Chairman of CHIPCREEN BIOSCIENCES, and Mr. Li Yan , President of HISUN PHARMACEUTICAL, signed a granting agreement, marking a milestone for the two parties to establish a long-term, stable and mutually beneficial strategic partnership.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Small Molecule Disease 40

NIH Director's Blog: Drug Development

APRIL 7, 2015

After a whirlwind tour of the cutting-edge robotics facility for high throughput screening of small molecules, she joined me and NCATS Director Dr. Chris Austin in announcing that, thanks to an innovative public-private partnership, an experimental drug originally developed to fight cancer is now showing promise against Alzheimer’s disease.

Disease 52

Disease Drugs Clinical Trials Science 52

The Pharma Data

JANUARY 17, 2021

This includes the potential to launch a pivotal phase 2/3 trial with a clearly differentiated drug candidate in PBC but will also allow us to further explore a select number of kidney related orphan diseases in which inflammation and fibrosis play a part.”, ”, said CEO Renée Aguiar-Lucander. About Calliditas.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

Drug Target Review

APRIL 16, 2024

In chemotherapy-resistant tumours, traditional drugs may have limited efficacy due to various drug resistance mechanisms or the inability to penetrate the tumour effectively. Peptides are relatively small molecules compared to mAbs, making them easier and less costly to produce and modulate.

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

Agency IQ

FEBRUARY 23, 2024

Workshop addresses oncology dose optimization across full span of development In a series of broad-ranging, frank discussions, attendees at a joint FDA-American Association of Cancer Research (AACR) workshop worked through opportunities and challenges for dose optimization across the span of cancer drug development activities.

Science 40

Science FDA Trials Clinical Pharmacology 40

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. Food and Drug Administration granted Breakthrough Therapy designation to France-based Inventiva’s experimental NASH treatment lanifibranor. Inventiva – The U.S.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

The Pharma Data

JANUARY 19, 2021

Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. About ALS-4.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

The Pharma Data

AUGUST 21, 2020

It’s a coalition of globally renowned academic institutions, pharmaceutical companies and nonprofit research organizations. The short-term goal of CARE is to provide a quick emergency response to the pandemic by testing existing drugs that were designed to treat other diseases against COVID-19.

Virus 52

Virus Small Molecule Licensing Licensing 52

The Pharma Data

MARCH 24, 2021

Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent micro coagulation (blood clots). Solid performance despite COVID-19 pandemic.

Therapies 52

Therapies Disease Vaccine Small Molecule 52